Bosentan [bosentan]
- Terms
-
bosentan monohydrát
Stayveer
-
4-t-Butyl-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide
Bosentan Anhydrous
Bosentan Monohydrate
Ro 47-0203
Ro-47-0203
Tracleer
A sulfonamide and pyrimidine derivative that acts as a dual endothelin receptor antagonist used to manage PULMONARY HYPERTENSION and SYSTEMIC SCLEROSIS.
- DUI
- D000077300 MeSH Browser
- CUI
- M000640413
- CAS
- Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)(2,2'-bipyrimidin)-4-yl)-
- History note
- 2019 (1994)
- Public note
- 2019; BOSENTAN was indexed under SULFONAMIDES 1995-2018; and under RECEPTORS, ENDOTHELIN/antagonists 1994
Allowable subheadings
- AD
- administration & dosage 1
- AE
- adverse effects
- AG
- agonists
- AA
- analogs & derivatives
- AN
- analysis
- AI
- antagonists & inhibitors
- BL
- blood
- CF
- cerebrospinal fluid
- CS
- chemical synthesis
- CH
- chemistry
- CL
- classification
- EC
- economics
- HI
- history
- IM
- immunology
- IP
- isolation & purification
- ME
- metabolism
- PK
- pharmacokinetics
- PD
- pharmacology 2
- PO
- poisoning
- RE
- radiation effects
- ST
- standards
- SD
- supply & distribution
- TU
- therapeutic use 1
- TO
- toxicity
- UR
- urine